Evidence map›Paper›PMID 39996873›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Incidence and Predictors of Acute Kidney Injury Following Advanced Ovarian Cancer Cytoreduction at a Tertiary UK Centre: An Exploratory Analysis and Insights from Explainable Artificial Intelligence.

Elizabeth Ratcliffe, Ciara Devlin, Sarika Munot, Timothy Broadhead, Amudha Thangavelu, Michela Quaranta, David Nugent, Evangelos Kalampokis, Diederick De Jong, Alexandros Laios

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elizabeth RatcliffeSchool of Medicine, University of Leeds, Leeds LS2 9LU, UK.ORCID 0000-0002-2051-7993
Ciara DevlinSchool of Medicine, University of Leeds, Leeds LS2 9LU, UK.ORCID 0009-0001-4136-3452
Sarika MunotDepartment of Gynaecologic Oncology, ESGO Centre of Excellence for Ovarian Cancer Surgery, St James's University Hospital, Leeds LS9 7TF, UK.
Timothy BroadheadDepartment of Gynaecologic Oncology, ESGO Centre of Excellence for Ovarian Cancer Surgery, St James's University Hospital, Leeds LS9 7TF, UK.
Amudha ThangaveluDepartment of Gynaecologic Oncology, ESGO Centre of Excellence for Ovarian Cancer Surgery, St James's University Hospital, Leeds LS9 7TF, UK.
Michela QuarantaDepartment of Gynaecologic Oncology, ESGO Centre of Excellence for Ovarian Cancer Surgery, St James's University Hospital, Leeds LS9 7TF, UK.
David NugentDepartment of Gynaecologic Oncology, ESGO Centre of Excellence for Ovarian Cancer Surgery, St James's University Hospital, Leeds LS9 7TF, UK.
Evangelos KalampokisInformation Systems Lab, Department of Business Administration, University of Macedonia, 54636 Thessaloniki, Greece.ORCID 0000-0003-4416-8764
Diederick De JongDepartment of Gynaecologic Oncology, ESGO Centre of Excellence for Ovarian Cancer Surgery, St James's University Hospital, Leeds LS9 7TF, UK.ORCID 0000-0003-0081-674X
Alexandros LaiosDepartment of Gynaecologic Oncology, ESGO Centre of Excellence for Ovarian Cancer Surgery, St James's University Hospital, Leeds LS9 7TF, UK.ORCID 0000-0002-4870-7393

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesThe incidence of acute kidney injury (AKI) following advanced epithelial ovarian cancer (EOC) surgery has not been extensively studied. This study aimed to investigate the incidence of AKI and identify preoperative and intraoperative predictors in patients undergoing advanced EOC cytoreduction using both traditional statistics and Artificial Intelligence (AI) modelling.

methodsRetrospective data were collected for 134 patients with a suspected or confirmed diagnosis of advanced EOC (FIGO Stage III-IV) who underwent surgical cytoreduction between January 2021 and December 2022 at a UK tertiary referral centre. AKI was diagnosed according to the KDIGO criteria. Data on 22 patient variables were extracted, including age, Charlson Comorbidity Index (CCI), procedure length, surgical complexity, and length of hospital stay. Logistic regression analysis was used for feature selection to identify AKI predictors, and an extreme gradient boost (XGBoost) model was applied to all variables related to AKI events.

resultsThe incidence of postoperative AKI was 6.72% (n=9). Predictive factors for AKI included younger age (OR = 0.942, p=0.037), lower CCI (OR = 0.415, p=0.015), longer procedure duration (OR = 1.006, p=0.019), and greater surgical effort (OR = 1.427, p=0.007). Patients with perioperative AKI experienced a doubling in the length of hospital stay (p=0.008). Mortality rates were similar between patients with and without AKI. AI-driven algorithms highlighted the complexity of AKI prediction and provided individual risk profiles, enabling future stratification and prompting different frequencies of AKI monitoring following cytoreduction.

conclusionsPredicting AKI is a complex task. This study found a lower-than-expected incidence of AKI following advanced EOC cytoreductive surgery. AKI is linked to heightened surgical risk-taking, underscoring the need for improved guidelines focusing on postoperative monitoring for targeted patients. Artificial Intelligence offers the potential for personalized AKI prediction.

Indexed as

Acute Kidney InjuryArtificial IntelligenceCarcinoma, Ovarian EpithelialCytoreduction Surgical ProceduresOvarian NeoplasmsPostoperative ComplicationsAdultAgedFemaleHumansIncidenceMiddle AgedRetrospective StudiesRisk FactorsTertiary Care CentersUnited Kingdomacute kidney injuryartificial intelligenceovarian cancersurgical cytoreduction

Identifiers

PMID39996873
PMCPMC11854794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.